Gene Zhu

Dr. Zhu brings over 17 years of regulatory experience to his role at MaxCyte. During his career, he has been instrumental in supporting companies receive regulatory approvals of several biologics, including approvals for the treatment of post-transplant lymphoproliferative disease (PTLD), breast cancer, lung cancer, rheumatoid arthritis, eczema, asthma, gout, cytokine release syndrome, etc.

Prior to joining MaxCyte, Dr. Zhu served as Head of Regulatory Affairs CMC at Atara Biotherapeutics. Previously, he held the positions of: Head of Regulatory Affairs CMC at Daiichi Sankyo, Inc., Senior Director of Regulatory Affairs CMC at Regeneron Pharmaceuticals, Senior Director of Regulatory Affairs CMC at Savient Pharmaceuticals, Inc., and Associate Director at Chugai Pharma USA. Dr. Zhu earned his PhD in genetic engineering from Ghent University and his BS from Fudan University.